Goodwin Procter, a national Am Law 50 firm, announced today that Grant P. Fondo has joined the firm’s Silicon Valley office as a partner in its Securities Litigation & White Collar Defense Group. Fondo comes to Goodwin from the U.S. Attorney’s Office for the Northern District of California, where he served as an Assistant U.S. Attorney in its Criminal Division for nearly five years. He will focus on representing technology, life sciences and venture capital clients in a wide range of litigation and investigative matters.

More >>

Cooley LLP announced today that it advised Spooky Cool Labs LLC in its acquisition by Zynga Inc. Spooky Cool Labs is a social gaming company focused on developing cutting edge social and mobile games.

More >>

VLP Law Group LLP is very pleased to announce that Patrick Lawler and Jacob Dy-Johnson have joined the firm’s Commercial Lending practice. Mr. Lawler joins VLP as a partner from the Corporate Finance group of the Los Angeles office of O’Melveny and Myers. Mr. Dy-Johnson joins VLP as counsel (he was previously in the Palo Alto office of Wilson Sonsini Goodrich & Rosati).

More >>

Davis Polk advised J.P. Morgan Securities LLC and Barclays Capital Inc. as representatives of the initial purchasers in connection with a Rule 144A offering by NetSuite Inc. of $310 million aggregate principal amount of 0.25% convertible senior notes due 2018.

More >>

Davis Polk advised Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC as representatives of the initial purchasers in connection with a Rule 144A offering by Concur Technologies, Inc. of an aggregate principal amount of $488.75 million of its 0.5% convertible senior notes due 2018, which included $63.75 million aggregate principal amount of notes from the full exercise of the initial purchasers’ over-allotment option. In addition, Davis Polk advised Deutsche Bank AG, UBS AG, Credit Suisse International and JPMorgan Chase Bank, National Association as counterparties to convertible note hedge and warrant transactions in connection with the offering.

More >>

Faegre Baker Daniels LLP is expanding its operations to Silicon Valley effective July 1, 2013. The office, which will be located at 1950 University Circle in Palo Alto, Calif., is being opened by intellectual property partners Calvin L. Litsey and David J.F. Gross, both of whom are relocating from the firm’s Minneapolis office.

More >>

Goodwin Procter attorneys recently advised the underwriters, led by Citigroup, BofA Merrill Lynch, Credit Suisse and Goldman Sachs, in the PennyMac Financial Services, Inc. (PennyMac) initial public offering of more than 12 million shares of common stock at $18 per share. Shares began trading on the New York Stock Exchange under ticker “PFSI”.

More >>

Davis Polk advised Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC as joint book-running managers in connection with the $140.4 million initial public offering of 9,686,171 shares of common stock of Portola Pharmaceuticals, Inc. (including 1,263,413 shares subject to the underwriters’ over-allotment option) at $14.50 per share. The common stock is listed on the Nasdaq Global Market under the symbol “PTLA.”

More >>

Kasowitz, Benson, Torres & Friedman LLP is pleased to announce that leading intellectual property litigator Steven C. Carlson has joined the firm as Managing Partner of its Silicon Valley office. Mr. Carlson litigates patent and trade secret cases through trial in fields across the technology spectrum, representing high-tech, pharmaceutical, biotechnology, and medical device companies before district courts, appellate courts and the International Trade Commission. His clients have included tech company SRI, molecular diagnostics company Cepheid and pharmaceutical firm Allergan Inc.

More >>

Cooley LLP announced today that it advised Portola Pharmaceuticals on its $140 million initial public offering. Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. It now trades on the NASDAQ Global Stock Market under the symbol “PTLA.”

More >>